EUVIMEDEUVIMED entdecken
Crossref

How to navigate an increasingly heterogeneous spectrum of resistance mechanisms in oncogene driven non-small cell lung cancer?

Charlotte De Bondt, Paul Van Schil

AME Clinical Trials Review · 2024

DOI: 10.21037/actr-23-35 ↗

Kurz gefasst

Fachartikel in der Zeitschrift AME Clinical Trials Review, 2024. Verfasst von Charlotte De Bondt und 1 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Zitieren

APA

Bondt, C. D., & Schil, P. V. (2024). How to navigate an increasingly heterogeneous spectrum of resistance mechanisms in oncogene driven non-small cell lung cancer?. AME Clinical Trials Review. https://doi.org/10.21037/actr-23-35

Vancouver

Bondt CD, Schil PV. How to navigate an increasingly heterogeneous spectrum of resistance mechanisms in oncogene driven non-small cell lung cancer?. AME Clinical Trials Review. 2024. doi:10.21037/actr-23-35

BibTeX
@article{Bondt2024,
  author = {Bondt, Charlotte De and Schil, Paul Van},
  title = {How to navigate an increasingly heterogeneous spectrum of resistance mechanisms in oncogene driven non-small cell lung cancer?},
  journal = {AME Clinical Trials Review},
  year = {2024},
  doi = {10.21037/actr-23-35}
}
Kostenlos starten →